SAB Biotherapeutics (SABS) Payables (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Payables data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Payables rose 33.32% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 33.32% YoY) and the FY2025 annual result came in at $3.1 million, up 59.64% from the prior year.
• Payables rose to $3.5 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.0 million in Q1 2022 to a low of $1.3 million in Q3 2024.
• A 5-year average of $3.0 million and a median of $2.6 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables sank 70.97% — and 2025, when it jumped 127.83%.
• Tracing SABS's Payables over 5 years: stood at $4.5 million in 2022, then plunged by 55.15% to $2.0 million in 2023, then decreased by 1.31% to $2.0 million in 2024, then surged by 59.64% to $3.1 million in 2025, then gained by 12.69% to $3.5 million in 2026.
• The last three Payables figures came in at $3.5 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.